Search 

CathPrint - a MedTech company founded in 2006 is based on a unique and patented technology that enables miniaturized, large scale, cost effective catheter and endoscopic applications.

Our mission is to improve patient management as well as increase patient safety by enabling advanced, reliable diagnostic and therapeutic catheters and endoscopes.

Although we are based in Stockholm, Sweden but we work closely with an international mixture of OEM manufacturers, sensor/electronics suppliers, and engineering consulting firms to offer product solutions to companies who wish to develop and sell their own catheters and miniaturized endoscopes.  Our key customers currently are small and medium sized European companies developing advanced catheters and endoscopes.

We offer CathPrint™- a patented design and manufacturing technology for the realization of advanced, reliable catheters and endoscopes. It is based on standard electronics production concepts; like flexible printed wire-boards and surface mounting of components. 

We have had a number of research projects with large companies. Today we are in the midst of establishing production for our first customer, whilst evaluating our technology for several other potential customers as well.

Hence, CathPrint is looking for an investment of 5 MSEK to further strengthen the organization as well as extend marketing and sales.

Chundsell Medicals AB was founded in 2007 based on the need for a more specific system, the Prostatype test system, to diagnose prostate cancer and to predict the survival prognosis for patients. The test also distinguishes between the aggressive and non-aggressive tumors.

The business idea is to market and sell to the global market a complete diagnostic system consisting of reagents, an instrument platform and evaluation software. We strive to develop and produce frontline product solutions designed for optimal user compliance as well as fulfillment of the highest quality demands. Our product system will meet an urgent medical need and will have a positive impact on the overall health economy as well as preserve the quality of life for thousands of men each year.

The patent pending Prostatype test is based on real- time-quantitative-PCR (qPCR) where we analyze the expression of a set of genes in cancer stem cells. The expression of these genes can with high statistical significance identify patients with aggressive tumors (20%) from the ones with non-aggressive tumors (80%). The results are based on a clinical endpoint study where patients have been followed-up on for more than 20 years. The results have shown that the gene signatures can classify different tumor types, indicate overall and cancer specific survival and serve as a guide to the urologist to choose therapy like prostate surgery, radiation, hormone treatment or watchful waiting.